Ana Lluch

18PUBLICATIONS
78CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical virologyMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 22, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas

|Apr 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Francesco Schettini, Nuria Chic, Fara Brasó-Maristany

|Mar 10, 2023
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells.

Sara S Oltra, Sara Colomo, Laura Sin

|Dec 08, 2022
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.

S Mouron, M J Bueno, A Lluch

|Nov 08, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.

Karama Asleh, Ana Lluch, Angela Goytain

|May 20, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.

Anna Adam-Artigues, Enrique J Arenas, Alex Martínez-Sabadell

Pageof 3

Frequent Collaborators

8 joint publications

Pilar Eroles

3 joint publications

Joan Albanell

3 joint publications

Carlos H Barrios

3 joint publications

Juan Miguel Cejalvo